Figure 6.

Serum anti-LTB IgG responses and LTB neutralization capacity. (A) Percentage of subjects responding with an at least 4-fold (solid) or at least 2-fold (open) titer increase in anti-LTB IgG in serum at any analyzed time point in groups receiving indicated numbers of doses of 5 × 10¹⁰ CFU oral ShigETEC or placebo (grey). (B) Individual anti-LTB serum IgG titers of all subjects in group 2C (4-dose regimen) with placebo recipient in grey, vaccinees with <4-fold titer increase in black and vaccinees with >4-fold titer increase in blue. (C) LTB neutralizing capacity of serum of all subjects of group 2C (4-dose regimen) at indicated dilution factor.